01675nam 2200457 450 991070722960332120160624094802.0(CKB)5470000002463214(OCoLC)952178269(OCoLC)995470000002463214(EXLCZ)99547000000246321420160624d2011 ua 0engurmn|||||||||rdacontentrdamediardacarrierHigher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D[Washington, D.C.] :Department of Health and Human Services, Office of Inspector General,2011.1 online resource (iv, 22 pages) color illustrationsTitle from title screen (viewed June 23, 2016)."August 2011.""OEI-03-10-00320."Includes bibliographical references.Higher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part DMedicareMedicaidPharmaceutical services insuranceUnited StatesAuditingDrugsPricesUnited StatesBrand name productsPricesUnited StatesMedicare.Medicaid.Pharmaceutical services insuranceAuditing.DrugsPricesBrand name productsPricesGPOGPOBOOK9910707229603321Higher rebates for brand-name drugs result in lower costs for Medicaid compared to Medicare Part D3310614UNINA